Schizophrenia

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

The National Institute of Mental Health has awarded a $3.4 million grant to professor Thilo Womelsdorf to study the underlying mechanisms of action for potential drugs to regulate cognitive function and brain network activity affected in schizophrenia without debilitating side effects. Read More

Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read More

Researchers discover how a protein may treat schizophrenia, including reversing working memory deficits, a hallmark of schizophrenia for which there is currently no treatment. Read More

Vanderbilt psychiatrists are probing brain circuit hyperactivity implicated in schizophrenia, with the idea that normalizing the hyperactivity may improve cognitive processes. Read More

Specific regions of the thalamus — a central brain region — are smaller in adults with psychotic disorders and youth at risk for psychotic disorders and are associated with cognitive impairment. Read More

The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found. Read More

Studies of relational memory function may reveal novel mechanisms for therapeutic intervention for patients in the early stages of psychosis. Read More

Functional MRI studies have revealed that targeting activation of certain brain regions may improve working memory and cognition in psychotic disorders. Read More

Inhibited temperament—a tendency to respond to novelty with wariness, fear or caution—may be a risk factor for schizophrenia that could be targeted for preventative interventions. Read More

Psychiatrists diagnose people with schizophrenia, ADHD, bipolar disorder and other mental illnesses by spending time with them, looking for the particular behavior symptoms of each. What follows can be a hit-or-miss series of medications and dosages until disruptive behaviors go away. By deciphering the circuitry of the medial frontal cortex… Read More

Vanderbilt University researchers are working to understand how people with schizophrenia experience emotion through their bodies. Read More

Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting. Read More

Brain imaging studies have implicated the connection between two brain regions in the pathophysiology of schizophrenia. Read More

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia. Read More

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice. Read More

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation. Read More

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More